Managing Acinetobacter baumannii infections
- 1 February 2019
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Infectious Diseases
- Vol. 32 (1), 69-76
- https://doi.org/10.1097/qco.0000000000000518
Abstract
We reviewed recent data about epidemiology of Acinetobacter baumannii, resistance mechanisms, and therapeutic options for severe infections caused by multidrug-resistant strains. A. baumannii is a major cause of nosocomial infections affecting mainly to debilitating patients in the ICU, although the spread to regular wards and to long-term care facilities is increasing. It is characterized by its great persistence in the environment and to have an extraordinary capability to develop resistance to all antimicrobials. Carbapenems may not be considered the treatment of choice in areas with high rates of carbapenem-resistant A. baumannii. Nowadays, polymyxins are the antimicrobials with the greatest level of in-vitro activity against A. baumannii. Colistin is the most widely used in clinical practice although polymyxin B seems to be associated with less renal toxicity. Colistin is administered intravenously as its inactive prodrug colistimethate. A loading dose of 9 million IU and subsequently high, extended-interval maintenance doses (4.5 million IU/12 h) are recommended. Combination therapy instead of monotherapy increases the rates of microbiological eradication although no clinical study has demonstrated a reduction in clinical outcomes (mortality or length of stay). The optimal treatment for multidrug-resistant A. baumannii nosocomial infections has not been established. There are no compelling data to recommend combination therapy for severe A. baumannii infections.Keywords
This publication has 63 references indexed in Scilit:
- The Success of Acinetobacter Species; Genetic, Metabolic and Virulence AttributesPLOS ONE, 2012
- The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant MenaceFrontiers in Microbiology, 2012
- Implications of endotracheal tube biofilm in ventilator-associated pneumonia response: a state of conceptCritical Care, 2012
- In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumanniiJournal of Antimicrobial Chemotherapy, 2011
- Potent Synergy and Sustained Bactericidal Activity of a Vancomycin-Colistin Combination versus Multidrug-Resistant Strains of Acinetobacter baumanniiAntimicrobial Agents and Chemotherapy, 2010
- Multiresistant Acinetobacter baumannii infections: epidemiology and managementCurrent Opinion in Infectious Diseases, 2010
- Colistin Heteroresistance in Acinetobacter and Its Association with Previous Colistin TherapyAntimicrobial Agents and Chemotherapy, 2008
- An increasing threat in hospitals: multidrug-resistant Acinetobacter baumanniiNature Reviews Microbiology, 2007
- Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumanniiAntimicrobial Agents and Chemotherapy, 2006
- Pharmacokinetic/pharmacodynamic profile for tigecycline—a new glycylcycline antimicrobial agentDiagnostic Microbiology and Infectious Disease, 2005